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Opinion statement
The outcome of patients with advanced soft tissue sarcomas (STS) has not improved much
during the last decade. Apart from non-pleomorphic rhabdomyosarcoma, adjuvant chemo-
therapy has no standard role in high risk STS. In metastatic disease little progress has been
made, but during recent years much effort has been put into the development of better clin-
ical study protocols, with stratification of patients to at least the most common histological
subtypes, preventing the dilution of potential treatment efficacy when measuring results
over the total heterogeneous group of STS. The outcome of patients with advanced STS is
however not only dependent on the introduction of new drugs, but also on the availability
of dedicated sarcoma centers in which multidisciplinary teams with the input of all experts
from different disciplines, such as pathology, radiology, nuclear medicine, surgery, orthope-
dics radiotherapy and medical oncology is present. Long delay, wrong histological diagno-
ses, under- and overtreatment are not in the favor of these patients, neither with regard to
outcome, nor with respect to short- and long-term toxicity. Disappointedly, centralization is
not a routine part of daily care of STS patients and their care givers. Patient advocacy groups
are more and more aware of the relevance of treatment in centers of expertise and are active
in guiding the patients to these hospitals. At the same time the sarcoma centers should be
pro-active in putting patients into clinical trials, also for rare indications within the STS
group, as only in this way a better outcome for this group of patients can be reached.
Introduction
Soft tissue sarcomas (STS) are a rare and heteroge-
neous group of mesenchymal malignancies. They
comprise 1–2 % of all maliganancies and encompass
about 50 histological subtypes. The outcome of the
disease is poor, with a median survival of about 1 year
in case of metastatic disease. Given the rarity and the het-
erogeneity of the disease, improvement in outcome for
STS as awhole is difficult to reach.However, with the bet-
ter understanding of the biology of at least certain sub-
types of STS and the opportunities ofmolecular diagnos-
tics new therapeutic options are on the horizon and are
currently being tested in clinical studies. Not surprisingly,
most of the attention from pharmaceutical companies
has always been put into the big four killers: lung-, co-
lon-, breast- and prostate cancer, and the awareness of
the importance of performing clinical studies in rare can-
cers was difficult to reach until 2000. At that time the
breakthrough of the targeted agent imatinib in gastro-in-
testinal stromal tumors (GIST) showed the oncological
world that even in rare diseases concepts of new treat-
ments can be born [1]. Since then a tremendous amount
of research has been put in understandingmore of the bi-
ology, sensitivity and resistance of this type of cancer.
Even the commonly used RECIST (Response Evaluation
Criteria In Solid Tumours) became debatable in themed-
ical treatment of GIST, and new criteria of response eval-
uation became necessary. Until now the CHOI criteria
have been the most widely used in this respect [2, 3].
In metastatic STS first line doxorubicin is the most
commonly used chemotherapeutic agent, either as a sin-
gle agent or in combination therapy with ifosfamide.
Whether combination therapy, apart from a higher
chance of inducing a response, also leads to a better sur-
vival is still unknown. The results of the European Orga-
nisation of Treatment and Development of Cancer
(EORTC) Soft Tissue and Bone Sarcoma Group (STBSG)
62012 study, expected in 2012, will hopefully give an
answer to this important question. Ifosfamide is applied
in many cases of STS, but the toxicity (especially bone
marrow, nephrotoxicity and encephalopathy) of themost
widely applied schedules is an important limiting factor,
especially in the elderly. Depending on registration and
reimbursement per country, also other chemotherapeutic
agents can be given, mostly restricted to certain tumor
types. Well-known examples are paclitaxel in angiosar-
coma, as well as gemcitabine with or without docetaxel
in other STS, and trabectedin in leiomyosarcoma and lip-
osarcoma. In recent years some new, potentially promis-
ing drugs have been tested in STS and—to a limited
extent—also in the rare group of bone sarcomas. Given
the rarity of the disease, national and international collab-
orations in performing studies in dedicated sarcoma cen-
ters is essential to make any progress in STS, as well as in
several types of bone sarcomas, such as Ewing sarcoma
(ES), osteosarcoma, and other orthopedic tumors. Several
national groups have been founded during recent years
which all aim at exploring new drugs in various histolog-
ical subtypes. Nevertheless, phase 3 studies are still scarce.
In 2002, Van Glabbeke et al. published results of
the database of EORTC STBSG in which, for phase 2
studies in STS, potential active and non active drug
results were distinguished, i.e. in pretreated patients
active drugs had a progression-free rate (PFR) of
39 % and 14 % at 3 and 6 months, respectively, while
inactive regimens had a PFR of 21 % and 8 %, respec-
tively [4]. For first-line therapy, a 6-month PFR of
more than 30–56 % (depending on histology) was de-
fined as a reference value for drug activity; for second-
line therapy, a 3-month PFR of more than 40 % would




Trabectedin is an alkylating agent that binds to the DNA minor groove. It was
originally isolated from the Caribbean sea squirt Ecteinascidea turbinata, but is
now synthetically manufactured. In recent years trabectedin (ET-743, Yon-
delis) has been granted orphan drug status in many countries for locally
advanced STS, refractory or unsuitable to receive standard chemotherapy,
consisting of doxorubicin and ifosfamide. The standard dose and regimen is
1.5 mg/m2 over 24 hours every 3 weeks, given over a central line with
dexamethasone premedication to decrease the severity of liver and bone
marrow toxicity. Other toxicities include nausea and fatigue and in rare cases
also rhabdomyolysis. Strict dose reduction schedules based on prior toxicity
and in between cycle safety laboratory measurements of bone marrow
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function, renal and liver function and serum creatinine phosphokinase are
mandatory and are to be adhered to by the treating physician’s team. Toxicity
does not seem to be cumulative, even after more than ten cycles. The efficacy
of trabectedin has been shown mainly for lipo- and leiomyosarcomas in nu-
merous phase II and compassionate use programs, although other STS
subtypes may also benefit equally from the drug, such as synovial sarcoma.
Remarkable efficacy was observed in myxoid liposarcoma with an approxi-
mately 50 % response rate in a retrospective study [5] and a 24 % partial re-
sponse rate and 13 % pathological complete remission rate in a recent
prospective neoadjuvant phase II study [6]. Only one randomized study has so
far been completed [7•]. This randomized phase II study comparing a weekly
3-hour with a 3-weekly 24-hour schedule favours the latter schedule with a
median time to progression of 3.7 months. However the lack of a randomized
phase III study has thus far been an omission in the clinical development path
of this drug. Therefore we welcome the current ongoing first line EORTC/
SARC phase IIB/III study (NCT01189253; “TRUST”) in patients with locally
advanced or metastatic STS. This study investigates the feasibility of a 3-hour
3-weekly infusion versus the standard 24-hour infusion, and the approach with
the best results is being further compared to 3-weekly doxorubicin in the
phase III part of the study with PFS as primary endpoint.
Eribulin
Eribulin mesylate (E7389, Halaven) is a synthetic analogue of halichondrin B,
which was originally isolated from marine sponges. Like taxanes it is a tubulin
targeting agent. It has shown activity in breast and lung cancer. The activity of
taxanes is restricted to certain subtypes of soft tissue sarcomas. Paclitaxel has
shown activity in angiosarcoma, and docetaxel has only shown efficacy in com-
bination with gemcitabine, predominantly in leiomyosarcoma. In a non-rando-
mised multistrata and multicenter phase 2 study the efficacy of eribulin was
evaluated [8]. Eribulin was administered in a dosage of 1.4mg/m2 on days 1 and
8 of a 3-week cycle until progression or limiting toxicity. In linewith other studies
of EORTC, the progression-free rate at 12 weeks (PFR 12weeks) was taken as end-
point of the study. In the study of Schöffski et al. 128 patients participated and
were stratified according to the histological subtype. The PFR 12weeks was 47% for
liposarcoma, 32% for leiomyosarcoma, 21% for synovial sarcoma and 19% for
other STS.Most serious toxicities (grades 3–4)were neutropenia, anemia, fatigue,
febrile neutropenia, mucositis and sensory neuropathy, and 5 % had increased
alanine aminotransferase serum levels. Based on this promising activity, cur-




Pazopanib (GW786034; Votrient) is a synthetic indazolpyrimidine, which
targets multiple kinases, including vascular endothelial growth factors
(VEGFR1-3) and platelet derived growth factors (PDGFR). Recently, pazo-
panib had been registered for the treatment of advanced renal cell cancer. In
a previous stratified phase 2 clinical trial in relapsed or metastatic soft tissue
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sarcoma (EORTC study 62043) the progression free rate at PFR 12weeks was 44%
in leiomyosarcomapatients, 49% in synovial sarcomapatients, 39% inpatients
with other types of STS, and 26 % in liposarcoma patients [9]. Based on this
promising activity a phase 3 study was designed by EORTC STBSG, in which
pazopanib was compared with placebo in a 2:1 fashion in patients with pro-
gressive non-adipocytic STS, who had had anthracyclines and standard treat-
ment for STS in their country. This so-called PALETTE trial (EORTC study
62072) was conducted in EORTC centers together with centers worldwide, no
crossover was allowed in the study [10••]. Themedian PFSwas 4.6monthswith
pazopanib compared to 1.6 month with placebo (hazard ratio 0.31, 95 % CI
0.24–0.40; PG0.0001). The final overall survival (OS) was 12.5 months with
pazopanib versus 10.7 months with placebo (HR 0.86; 0.67–1.10; P=0.25).
Pazopanib was generally well tolerated. Most common adverse events were:
fatigue, diarrhea, nausea, weight loss and hypertension. Although the driving
factor of thismultikinase inhibitor is unknown, pazopanib is seen as a welcome
member in the family of active drugs in STS. Many studies with combination
treatments are ongoing.
Regorafenib
Regorafenib (BAY73-4506) is an oral tyrosine kinase inhibitor targeting multiple
receptors, including VEGFR1-2, PDGFR beta, FGFR1 and KIT, and multiple key
players in the intracellular signal transduction pathways. The dosing schedule is
160 mg/day d1-21 every 4 weeks. The main toxicities include hand-foot skin
reactions and hypertension. The drug was recently found to be active in a phase
III study in third line metastatic colorectal cancer and has the longest progression
free rate of any drug tested in a third line GIST study [11]. Recently, a phase
III study in patients that failed prior treatment with imatinib and sunitinib was
completed and results will be presented at the ASCO 2012 annual meeting.
Sorafenib
Sorafenib (Nexavar) is an oral tyrosine kinase inhibitor that, amongst
others, blocks VEGFRs, KIT, PDGFRs and RAF. It was the first targeted agent
found to be active against metastatic clear cell renal cancer and is also
registered for non-resectable hepatocellular carcinoma. The standard dose
is 400 mg twice daily and toxicities are comparable to other oral angiogenesis
inhibitors. Sorafenib shows varying degree of activity in phase II studies
in multiple sarcoma subtypes including third line GIST, angiosarcoma and os-
teosarcoma [12–14]. Despite encouraging progression free rates and some
responses we have to realize that progression rate before entry into the
studies was not clearly defined. This, together with the lack of phase III studies in
the more frequent subtypes such as GIST, leaves us with the conclusion that
sorafenib has not yet a clearly defined role in the treatment of sarcoma.
Nilotinib
Nilotinib (Tasigna) is an oral tyrosine kinase inhibitor that inhibits BCR-ABL,
KIT and PDGFRs and is active in some imatinib resistant forms of KIT
and less sensitive to some drug efflux pumps than imatinib. The drug was re-
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cently registered in CML and the therapeutic dose is 400 mg twice daily on a
continuous schedule. The main toxicities include fatigue and gastrointestinal
complaints. After promising activity in a phase I study [15] and a compassionate
use study [16], both in imatinib and sunitinib resistant GIST, a phase III
study was undertaken. In this study imatinib and sunitinib refractory or intol-
erant patients were randomized in a 2:1 ratio between nilotinib and best sup-
portive care, that may include retreatment with imatinib or sunitinib [17•]. In
the main analysis of this paper the median PFS was similar between the two
arms. There was a discrepancy between investigator and central RECIST reading,
emphasizing the drawbacks of RECIST-PFS as primary endpoint in these
patients. In anunplannedpost hoc analysis in true third line patients progressive
on both prior imatinib and sunitinib, a more than 4 months survival benefit
of nilotinib was observed, despite cross-over availability to nilotinib in the best
supportive care arm. In retrospect, the design of this study has not been an
optimal one, which, unfortunately, has negative consequences
with regard to registration of this drug for this indication.
Masitinib
Masitinib (AB1010) is a novel oral tyrosine kinase inhibitor of c-KIT, PDGFR
and Lyn, making it particularly interesting for inhibition of mast cells in
systemic mastocytosis in dogs and humans. The drug has greater preclinical
activity than imatinib in some KIT isoforms. The recommended dose is 7.5–
12 mg/kg/d in a continuous schedule and main toxicities include rash, as-
thenia, diarrhea, nausea and muscle cramps, as with imatinib. In a recent first
line phase II study in metastatic GIST the drug showed remarkable activity
with a disease control rate of 97 % and an estimated PFS of 41.3 months
[18]. Based on these results in first line treatment of GIST and based on
promising activity in imatinib-resistant GIST patients in the phase I study
[19], it was decided to start two randomised studies in metastatic GIST—a
first line phase III study (NCT00812240) comparing masitinib to imatinib
and a second line phase II study (NCT01506336) comparing mastinib to
sunitinib.
Ridaforolimus
Ridaforolimus (AP23573, MK-8669, formerly deforolimus) is an inhibitor of
mammalian target of rapamycin (mTOR), an integral component of the
phosphatidyl 3-kinase (P13K)/AKT signaling pathway. Deregulation of the
PI3K/AKT pathway is frequently observed in a variety of malignancies. In a
multicenter, open-label, single-arm, phase II trial the antitumor activity of
ridaforolimus in patients with distinct subtypes of advanced sarcomas was
tested [20]. Patients with metastatic or unresectable soft tissue or bone sar-
comas received ridaforolimus 12.5 mg administered as a 30-minute intra-
venous infusion once daily for 5 days every 2 weeks. The primary end point
was clinical benefit response (CBR) rate (complete response or partial re-
sponse or stable disease ≥16 weeks). A total of 212 patients were treated in
four separate histological cohorts: primary bone sarcomas, leiomyosarcomas,
liposarcomas, and other soft-tissue sarcomas. Sixty-one patients (28.8 %) of
this pretreated population achieved CBR, with a median PFS of
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15.3 weeks and a median OS of 40 weeks. RECIST confirmed response
rate was 1.9 % (n=4); three responses were observed in bone sarcomas.
Adverse effects mainly consisted of fatigue, stomatitis, hypertriglyceride-
mia, anemia, rash, and nausea. A phase 3 study was designed in which
patients, after initial chemotherapy in advanced sarcomas, were randomised
between ridaferolimus and placebo as maintenance therapy. Results of this
SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Rida-
forolimus) study were reported at ASCO 2011 [21]. In this phase 3 study STS
and bone sarcoma patients received ridaforolimus 40mg orally for 5 days/week
vs. placebo as maintenance therapy following stable disease or better response
to prior chemotherapy. A total of 711 patients were randomised, and the
median PFS increased from17.7weeks in the ridaforolimus arm comparedwith
14.6 weeks in the placebo arm (PG0.001); no difference in overall survival
was observed. Although an interesting concept of testing maintenance therapy
in advanced sarcoma, the results of SUCCEED are not in favor of ridaforolimus
given the minimal improvement in PFS and the non-negligible adverse
events of this drug [22].
Denosumab
Denosumab (Xgeva) is a human antibody that inhibits RANK ligand
(RANKL), a key mediator in osteclast-like giant cells and their precursors.
Inhibition of RANKL by denosumab in giant cell tumours of bone was
expected to inhibit bone destruction and giant cells. The drug is being ad-
ministered subcutaneously and its toxicity is limited to sporadic acute phase
reactions, hypocalcaemia and infrequently osteonecrosis of the jaw. The drug
is being registered at a lower dose in bone metastases and in osteoporosis.
The dose in studies in giant cell tumor of bone is 120 mg subcutaneously on
day 1, 8, 15, 28 and then q 28 days. The activity of denosumab in giant cell
tumour of bone is, as expected for this “Rolls Royce of giant cell dependent
tumours,” astonishing. Virtually all patients experience pain reduction and
predefined clinical efficacy of 86 % [23••]. Preliminary unpublished data
suggest that surgery after denosumab treatment is easier than without due to
the formationof a calcified boundary around the tumor.Currently the activity of
the drug is being investigated in a larger phase II study (NCT00680992) in two
cohorts: non-resectable and metastatic disease. This drug is certainly one of the
most active drugs in oncology in the last decades and deserves registration for
this indication in our opinion.
Imatinib: “old” drug, new indications
Imatinib adjuvant
Imatinib (Glivec/Gleevec) was the first tyrosine kinase inhibitor that was regis-
tered in oncology, initially for CML and then for metastatic GIST. The standard
dose is 400 mg once daily for metastatic GIST, and twice daily for exon 9
mutated GIST. Recently the landscape of adjuvant treatment for GIST has
changed. After the first adjuvant 1-year imatinib study in GISTs 92 cm
that showed a PFS benefit but noOS advantage [24], a second adjuvant study in
high risk GIST changed the daily practice. The SSG study showed not only a
PFS but also an OS advantage in c-KIT positive high risk GIST patients treated
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with imatinib for 3 years compared to 1 year [25••]. International guidelines were
adapted to incorporate 3 years of adjuvant imatinib as the gold standard, except for
known imatinib resistant mutations, such as PDGFR D842V mutated GIST.
Imatinib-PVNS
The role of imatinib in diffuse type tenosynovial giant cell tumour (TGCT),
also known as pigmented villonodular synovitis (PVNS), was first described
in a case report by Blay et al. [26]. The proposed mechanism of action is as
follows: this benign, but sometimes recurrent and then invalidating tu-
mour, overexpresses colony stimulating factor 1 (CSF1) that may result
from a t(1 ;2) translocation. Active CSF1 attracts inflammatory cells that
in its turn express CSF1R (receptor) through a paracrine or “landscape” effect.
Imatinib inhibits CSF1R (albeit in the high nanomolar range) and therefore is
an interesting drug for this disease. In a retrospective study of 29 patients ima-
tinib displayed interesting activity (overall response rate 19 % and 74 % stable
disease) [27]. However the benefits of alleviating morbidity must be balanced
against potential toxicity of chronic imatinib therapy in this relatively young
patient population. In this study the median age was 41 years. Currently a
prospective phase II study is underway studying the effect of nilotinib in this
patient population (NCT01261429). More specific CSF1R inhibitors may be
needed for this disease.
Imatinib-Chordoma
Chordomas that are not amenable to radiotherapy or surgery can lead to
severe morbidity, and therefore systemic treatment options are being ex-
plored. Recently, promising results of a phase II study were published [28].
Based on the fact that chordomas express the PDGFRs and based on some
case reports, imatinib was the candidate to test in this study. Patients with
progressive chordomas received 800 mg/d until progression. The response
rate was 2 % with a 64 % clinical benefit rate as defined by absence of
progression at 6 months. Due to the rarity of this disease probably no
randomised studies will be undertaken to fully understand the effect of
imatinib. These results indicate that in the absence of other treatment
options or clinical studies imatinib is a reasonable treatment option in
symptomatic progressive patients.
Imatinib-Desmoid
Desmoid type aggressive fibromatoses are rare benign, but locally ag-
gressive tumours, sometimes associated with familial adenomatous
polyposis. When desmoid are unresectable systemic treatment is often
initiated with anti-estrogens, NSAIDs or even chemotherapy. The effect
of these treatments are difficult to judge for several reasons. First, rare
spontaneous regressions may overestimate treatment effect; second,
again no clearly defined growth rate before start of treatment is avail-
able in this often indolent disease; and third, prospective studies are
scarce and randomised studies are lacking. Against this background the
recently published phase II study of imatinib in this disease, showing an
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objective response rate of 6 % and 1-year progression free survival of
66 % is promising, but should be interpreted with care [29].
Imatinib-DFSP
Dermatofibrosarcoma protuberans (DFSP) is a dermal sarcoma that is
frequently characterized by an activated platelet derived growth factor
receptor beta (PDGFR-B) as a result of a translocation between chro-
mosome 17 and 22. This tumor rarely metastasizes, mainly in case of
fibrosarcomatous (FS) progression, and has a tendency to recur after
surgery of large lesions or after limited surgery at difficult locations such
as the head and neck area. As imatinib inhibits PDGFR-B signal trans-
duction multiple studies were undertaken to study the effect of this drug
in this rare disease entity. The combined results of two uncompleted
phase II studies of EORTC and SWOG show a clear benefit of imatinib
with a high response rate approaching 50 %, including DFSP with FS
progression, regardless of the dose (400 mg or 800 mg daily) [30].
Emerging treatments
IGF
The insulin like growth factor-1 receptor (IGF-1R) pathway transduces ex-
tracellular signals intracellularly to mediate cell proliferation, growth, and
survival. IGF-1R is activated on engagement by the growth factor ligands IGF-
1 and IGF-2, resulting in receptor autophosphorylation. IGF-1R activity is
also regulated by six IGF binding proteins, which lead to either promote or
antagonize IGF-1R signaling by binding with IGF ligands in the circulation.
This induces activation of multiple signaling cascades, including the PI3K/
AKT/mTOR pathway which, when aberrantly activated, promotes the onco-
genic phenotype. Several lines of evidence have suggested that IGF-1R sig-
naling is critical to the biology of, for example, Ewing sarcoma (ES) [31, 32].
Olmos reported about promising effects of anti-IGF1R antibody figitimumab
(CP751871) in a phase 1 study with refractory sarcomas [33]. Since then a
couple of studies were executed with IGF-1R antibodies. Pappo et al. pub-
lished about 115 patients who received the monoclonal IGF-1R antibody
R1507 either at doses of 9 mg/kg intravenously once a week or 27 mg/kg
intravenously every three weeks [34]. The overall complete and partial re-
sponse was 10 %, with a median duration of response of 29 weeks (range,
12–94 weeks). The median OS was 7.6 months (95 % CI, 6–9.7 months).
Ten of 11 responses were observed in patients who presented with bone
tumors (P=0.016). At the same time a phase 1/2 study was reported with
figitimumab in patients with ES, and other bone and STS sarcomas [35]. In
the phase 2 part of the study, 107 patients with ES received figitumumab at
30 mg/kg every 4 weeks for a median of 2 cycles (range, 1–16). Of 106
evaluable and in general heavily pretreated patients, 15 had a PR (overall
response rate, ORR 14.2 %) and 25 had stable disease. Median OS was
8.9 months. Importantly, pretreatment free IGF-1 levels discriminated be-
tween short and long OS. Simultaneously, Fleuren et al. showed in ES and
osteosarcoma xenografts visualization with (111)In-R1507 immuno-SPECT
ofmembranous IGF-1R expression and target accessibility [36]. Although in this
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way non-invasive prediction of therapy response to IGF-1R therapy (e.g. R1507)
could be developed also for clinical use, unfortunately quite a couple of phar-
maceutical companies have decided to stop the development of IGF1-R anti-
body programs. Results of IGF-1R combination studies [37] are promising and
studies with (dual) tyrosine kinase inhibitors are urgently awaited.
ALK
Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neo-
plasm characterized by a spindle-cell proliferation with an inflammatory infil-
trate. Approximately half of IMTs carry rearrangements of the anaplastic
lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK
expression. Recently, a lasting partial response to the ALK inhibitor crizotinib
(PF-02341066), known for its striking clinical activity in non-small-cell lung
cancers with EML4-ALK rearrangements, was reported in a patient with ALK-
translocated IMT, as compared with no observed activity in another patient
without the ALK translocation [38•]. These results support the dependence of
ALK-rearranged tumors on ALK-mediated signaling and warrants further study
in IMTs. Recently, in 189 paraffin-embedded rhabdomyosarcoma (RMS) tumor
specimens from 145 patients ALK aberrations on genomic and protein levels
were found to occur frequently and were related to disease progression and
outcome [39]. Therefore, the oncogenic role of ALK and the potential targeted
treatment with ALK inhibitors in RMS deserve further research.
MET
Hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, c-Met,
have been implicated in the growth and progression of a variety of solid
human tumors. Inhibition of HGF/SF:c-Met signaling may provide a
novel therapeutic approach for treating human tumors. Recently it was
shown that in clear cell sarcoma (CCS), known for its chemoresistance,
blocking c-Met activity with a small-molecule inhibitor (SU11274) or a
neutralizing antibody to its ligand HGF/SF (AMG 102) CCS cell growth
was significantly reduced in culture [40]. Also in leiomyosarcoma
interrupting autocrine and/or paracrine HGF/SF:c-Met signaling with
AMG 102 had profound antitumor effects [41].
Alveolar soft part sarcoma (ASPS) is a rare chemoresistant STS which
is characterized by the presence of a specific chromosomal translocation
encoding the chimeric transcription factor (ASPL-TFE3) that activates ex-
pression of MET. In eight patients immunohistochemical staining dem-
onstrated 100 % TFE3 positivity and 75 % MET positivity with a
strong association between TFE3 expression and MET positivity with cor-
relation coefficient of 0.808 (P=0.02) [42]. The high expression of MET in
ASPL-TFE3 (+) ASPSmayunderscore the potential role of targeted agents against
MET in ASPS.
In 2012, the EORTC study 90101 “CREATE” (NCT01524926) will
start. This cross-tumoral phase 2 study will address the issue of ALK
and Met driven tumors with crizotinib (PF-02341066). Four strata for
sarcomas will be part of CREATE: IMT, alveolar RMS, CSS and ASPS.
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